Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Company Overview

Lexeo Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments. Lexeo’s lead programs are designed to optimize receptor selectivity and pharmacokinetics, with the goal of delivering rapid onset of action and durable therapeutic benefits in both inpatient and outpatient settings.

To advance its clinical development efforts, Lexeo collaborates with academic institutions and contract research organizations across North America and Europe. These partnerships support ongoing Phase 1 and Phase 2 studies, as well as formulation and biomarker development activities that underpin the company’s regulatory strategy.

Headquartered in the United States, Lexeo Therapeutics is led by a management team with extensive experience in neuroscience research, drug development and regulatory affairs. The company aims to address significant unmet needs in mental health by translating cutting‐edge science into safe, effective treatments for patients worldwide.

Key Stats

• Today's Range: $5.01 to $5.47
• 50-Day Range: $5.09 to $7.44
• 52-Week Range: $2.51 to $10.99
• Volume: 787,385 shs
• Average Volume: 712,701 shs
• Market Capitalization: $399.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.88
• Consensus Rating: Moderate Buy

Lexeo Therapeutics Stock Analysis - MarketRank™

Lexeo Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 681st out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lexeo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lexeo Therapeutics has a consensus price target of $18.88, representing about 270.8% upside from its current price of $5.09.

Amount of Analyst Coverage

Lexeo Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexeo Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexeo Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexeo Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.57% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 18.92, which indicates bearish sentiment.

Change versus previous month

Short interest in Lexeo Therapeutics has recently increased by 3.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexeo Therapeutics does not currently pay a dividend.

Dividend Growth

Lexeo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.93

News Sentiment

Lexeo Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Lexeo Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for LXEO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $397,156.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Lexeo Therapeutics is held by insiders.

Percentage Held by Institutions

60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LXEO
• Previous Symbol: NASDAQ:LXEO
• CIK: 1907108
• Web: www.lexeotx.com
• Phone: 212-547-9879
• Fax: N/A
• Employees: 58
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Lexeo Therapeutics: $18.88
• High Price Target: $30.00
• Low Price Target: $10.00
• Potential Upside/Downside: +270.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.48%
• Return on Assets: -41.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.16
• Quick Ratio: 11.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.95 per share
• Price / Book: 1.73

Miscellaneous

• Outstanding Shares: 78,520,000
• Free Float: 74,360,000
• Market Cap: $399.67 million
• Optionable: Not Optionable
• Beta: 1.52